Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
|Articles|March 12, 2014
- Immunotherapy (Issue 2)
- Volume 2
- Issue 1
The Outlook for CAR-Modified T Cells
Author(s)Renier J. Brentjens, MD, PhD
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the outlook for CAR-modified T cells.
Advertisement
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the outlook for CAR-modified T cells.
Read more about CAR-modified T cells and other immunotherapies for B-cell malignancies > >
Articles in this issue
over 12 years ago
B-Cell Malignancies Faring Well With Immunotherapiesover 12 years ago
Update on Immunotherapy and Targeted Combination Therapiesover 12 years ago
How Immunotherapies are Changing the Treatment of Melanomaover 12 years ago
Progress Made With PD-L1 as Predictive Biomarkerover 12 years ago
Oncolytic Viral Therapies About to Spreadover 12 years ago
The Future of Immunotherapy Treatments in Lung Cancerover 12 years ago
Checking in on Checkpoint InhibitorsAdvertisement
Related to this article
The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5